A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT ID: NCT06824467

This clinical trial is studying a new treatment called sacituzumab tirumotecan (MK-2870) for women with platinum-sensitive recurrent ovarian cancer. The trial aims to find out if this treatment is ...

Recruiting

Phase: PHASE3 Type: interventional Locations: Goyang Si, Kyonggi Do, Korea, Republic Of, Omaha, Nebraska, United States +27 more

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

NCT ID: NCT06890338

This clinical trial is designed to evaluate the safety and effectiveness of a combination treatment using two drugs, carboplatin and mirvetuximab soravtansine (often called MIRV), for women with ad...

Not yet recruiting

Phase: PHASE2 Type: interventional

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

NCT ID: NCT04657068

This clinical trial is investigating a new drug called ART0380 for treating advanced or metastatic solid tumors, including types of ovarian cancer. The main goals are to find out the safest dose of...

Recruiting

Phase: PHASE1 Type: interventional Locations: Madrid, , Spain, Denver, Colorado, United States +68 more

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT ID: NCT05739981

This clinical trial, known as IMNN-001, is looking at a new treatment for women with advanced ovarian, fallopian tube, or primary peritoneal cancer. The study aims to find out if adding a drug call...

Recruiting

Phase: PHASE1 Type: interventional Locations: New York, New York, United States, Houston, Texas, United States +1 more

Study of AVZO-021 in Patients With Advanced Solid Tumors

NCT ID: NCT05867251

This clinical trial is studying a new oral medication called AVZO-021, which is designed to treat patients with advanced solid tumors. The main goals of the study are to understand how safe the med...

Recruiting

Phase: PHASE1 Type: interventional Locations: Tampa, Florida, United States, Sarasota, Florida, United States +8 more

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

NCT ID: NCT06856499

This clinical trial is studying the safety and effectiveness of two medications, Cirtuvivint and Olaparib, for women with certain types of advanced ovarian cancer that have not responded to platinu...

Not yet recruiting

Phase: PHASE1 Type: interventional Locations: Aurora, Colorado, United States, Aurora, Colorado, United States

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer

NCT ID: NCT06994195

This clinical trial is studying a new treatment called BL-B01D1 for patients with certain types of recurrent ovarian cancer that do not respond to platinum-based chemotherapy. The trial aims to see...

Not yet recruiting

Phase: PHASE3 Type: interventional Locations: Shanghai, Shanghai, China

A Beta-only IL-2 ImmunoTherapY Study

NCT ID: NCT05086692

This clinical trial, called the Beta-only IL-2 ImmunoTherapY Study, is looking to test a new treatment called MDNA11 for patients with advanced solid tumors, which are types of cancer that have spr...

Recruiting

Phase: PHASE1 Type: interventional Locations: San Diego, California, United States, Baltimore, Maryland, United States +28 more

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

NCT ID: NCT05281471

The OnPrime study is a clinical trial that is investigating a new treatment approach for women with certain types of ovarian cancer that have not responded well to standard chemotherapy, known as p...

Recruiting

Phase: PHASE3 Type: interventional Locations: Ann Arbor, Michigan, United States, Houston, Texas, United States +33 more

A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018

NCT ID: NCT04590326

This clinical trial is looking at a new drug called REGN5668 to see how safe it is and how well it works when combined with other treatments for cancers like ovarian cancer, fallopian tube cancer, ...

Recruiting

Phase: PHASE1 Type: interventional Locations: Boston, Massachusetts, United States, Philadelphia, Pennsylvania, United States +29 more

REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

NCT ID: NCT06710548

The REVITALIZE clinical trial is studying a program designed to help reduce fatigue and improve daily life for women with ovarian cancer who are receiving a specific type of treatment called PARP i...

Recruiting

Phase: NA Type: interventional Locations: Boston, Massachusetts, United States, Boulder, Colorado, United States +2 more

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT ID: NCT04606914

This clinical trial is studying a new treatment approach for women with advanced-stage ovarian, fallopian tube, or primary peritoneal cancer. Specifically, it is looking at the combination of two d...

Recruiting

Phase: PHASE2 Type: interventional Locations: Birmingham, Alabama, United States

A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer

NCT ID: NCT06545617

This clinical trial is studying a new treatment called BAT8006 for women with platinum-resistant ovarian cancer, which is a type of cancer that doesn't respond well to standard chemotherapy. The go...

Not yet recruiting

Phase: PHASE1 Type: interventional

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

NCT ID: NCT05870748

The REFRaME-O1 clinical trial is studying a new treatment called luveltamab tazevibulin to see how well it works and how safe it is compared to standard chemotherapy for women with certain types of...

Recruiting

Phase: PHASE2 Type: interventional Locations: Westmead, New South Wales, Australia, Baltimore, Maryland, United States +39 more

HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

NCT ID: NCT06014190

This clinical trial is studying a new treatment called HS-20089 for patients with ovarian and endometrial cancer that has come back or spread to other parts of the body. HS-20089 is a special type ...

Recruiting

Phase: PHASE2 Type: interventional Locations: Xi'an, Shanxi, China, Shenyang, Liaoning, China +28 more

RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

NCT ID: NCT06173037

This clinical trial is studying a new treatment called RC88 for women with certain types of advanced ovarian cancer, including fallopian tube and primary peritoneal cancer, who have not responded t...

Recruiting

Phase: PHASE2 Type: interventional Locations: Guangzhou, Guangdong, China, Nanjing, Jiangsu, China +39 more

Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype

NCT ID: NCT05574673

This clinical trial is looking at women with epithelial ovarian cancer, which is a type of cancer that starts in the cells on the surface of the ovaries. The study aims to understand how certain ge...

Recruiting

Type: observational Locations: København ø, Sjaelland, Denmark

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

NCT ID: NCT05065021

This clinical trial is exploring how genetic information from blood and tumor samples can help determine the best treatments for women with ovarian, fallopian tube, or primary peritoneal cancer who...

Recruiting

Phase: PHASE2 Type: interventional Locations: Toronto, Ontario, Canada

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

NCT ID: NCT06063070

This clinical trial is studying a combination treatment of two medications, fluzoparib and bevacizumab, for women with advanced ovarian cancer that has not tested positive for certain genetic mutat...

Not yet recruiting

Phase: PHASE2 Type: interventional Locations: Guangzhou, Guangdong, China

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

NCT ID: NCT05494580

This clinical trial is exploring a new treatment for women with platinum-resistant ovarian cancer, which means their cancer has not improved after receiving platinum-based chemotherapy. The study i...

Recruiting

Phase: PHASE1 Type: interventional Locations: Guangzhou, , China

Main Menu

Clinical Trials for Primary Peritoneal Cancer

20 Active Trials Found

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Study of AVZO-021 in Patients With Advanced Solid Tumors

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer

A Beta-only IL-2 ImmunoTherapY Study

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018

REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Related Conditions